Predicting Treatment Response in Colorectal Cancer
Author Information
Author(s): Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, Lena M De, Allegra C J, Johnston P G
Primary Institution: Clinical Experimental Oncology Laboratory and Histopathology Service, Medical Oncology, Oncology Institute, Bari, Italy
Hypothesis
Can p53 and thymidilate synthase expression predict clinical response to chemotherapy in advanced colorectal cancer patients?
Conclusion
The study suggests that thymidilate synthase expression is a better predictor of chemotherapy response than p53 expression in advanced colorectal cancer patients.
Supporting Evidence
- 49% of tumors expressed p53, while 50% showed TS immunostaining.
- Objective response was significantly higher in TS-negative tumors compared to TS-positive tumors.
- Logistic regression confirmed a significant association between TS status and clinical response.
Takeaway
Doctors can use certain markers in tumors to guess how well chemotherapy will work for patients with advanced colon cancer.
Methodology
The study analyzed p53 and thymidilate synthase expression in tumor samples from patients treated with chemotherapy.
Potential Biases
Potential biases in patient selection and retrospective analysis.
Limitations
The study is retrospective and may not account for all variables affecting treatment response.
Participant Demographics
Advanced colorectal cancer patients treated with chemotherapy.
Statistical Information
P-Value
P< 0.04; P< 0.03; two-sided P< 0.05
Confidence Interval
95% CI 8.34–1.01; 95% CI 2.85–1.26
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website